Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 04, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 970,000 ordinary shares of 25 pence each.
- Purchase Price: 1,540.1906 pence per share.
- Treasury Shares Held: 160,414,678 shares (post-transaction).
- Shares in Issue: 5,818,719,784 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 970,000 shares on May 04, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 970,000 share repurchase based on the disclosed price of 1,540.1906 pence per share.
- Confirm the updated total share capital structure (5,818,719,784 shares in issue plus 160,414,678 Treasury shares).
- Review the original shareholder resolution from the May 25, 2005 Annual General Meeting to understand the full scope of the authorized buyback program.